Melbourne’s Cell Therapies is set to become a global hub for the manufacture of cutting-edge CAR T-cell therapy to treat children and young adults with aggressive blood cancer.
Federal Health Minister Greg Hunt on Monday announced the government will reimburse Kymriah® (tisagenlecleucel, formerly CTL019) following an approval from the Medical Services Advisory Committee (MSAC).
Kymriah is an immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient’s own T-cells, genetically reengineered and programmed to recognise and kill cancer cells.
Today’s announcement funds Kymriah for paediatric and young adult patients up to 25 with B-cell precursor acute lymphoblastic leukaemia (ALL) who relapse or do not respond to initial therapy.
This follows a recent $105 million announcement from the Australian Government and Peter Mac which will more than double the Cell Therapies current manufacturing footprint.
“We are delighted by Novartis’ announcement and we look forward to the next stage of our relationship with them,” Chief Scientific Officer of Cell Therapies A/Prof Dominic Wall said.
“This new high-throughput facility will allow an increased production to 1,000 patient doses per year, up from around 50 currently”
“This in turn will create over 50 new highly skilled manufacturing jobs and means we have the ability to supply cell products across Australia and the region.
Kymriah is the only chimeric antigen receptor T-cell therapy approved by the Therapeutic Goods Administration in Australia”
About Cell Therapies Pty Ltd
Cell Therapies is a leading provider of cGMP contract manufacturing and deployment services for cell and gene therapy products in the Asia Pacific. Cell Therapies is dedicated to enabling patient access to, and furthering the development of, these ground breaking therapies on behalf of clients from around the world. Building on more than 15 years’ experience and strategic partnerships with our owner, Peter MacCallum Cancer Centre in Melbourne Australia, we provide a complete process development and GMP product supply service from translational studies through to commercial supply and can serve as a single access point for regional deployment of cellular therapies for our clients. We have TGA licences that allow us to safely manufacture and supply these CAR-T therapies to patients in Australia.